CALICI (CEO Jaemoon Choi), an AI-based drug discovery platform company, has signed an MOU with global compound supplier Enamine to collaborate on compound supply and the development of new drugs and functional materials.

The partnership will utilize CALICI’s AI platform Pharmaco-Net® to support compound development from early discovery to practical experimentation. The agreement follows initial discussions at international conferences, including CPHI Barcelona 2023 and Bio EUROPE 2023, and was formalized at Bio KOREA 2024.

Dr. Iaroslava Kos of Enamine said, “This collaboration allows us to provide optimized compound services and fully meet our clients’ needs.”
CEO Jaemoon Choi added, “Through Enamine’s support, researchers worldwide can access experimentally validated compounds derived from Pharmaco-Net®.”